Major pharmaceutical companies continually research and develop new medications and treatments, which must be shown to be safe and effective before doctors can prescribe them to patients. Through colorectal cancer clinical trials, researchers test the effects of new medications on a group of volunteers with colorectal cancer. Following a strict protocol and using carefully controlled conditions, researchers evaluate the investigational drugs under development by measuring the ability of the new drug to treat colorectal cancer, its safety, and any possible side effects.
Some patients with colorectal cancer are reluctant to take part in clinical trials for fear of getting no treatment at all for their colorectal cancer. This is simply not true. Patients with colorectal cancer who participate in colorectal cancer clinical trials receive the most effective therapy currently available for the colorectal cancer -- or they may receive colorectal cancer treatments that are being evaluated for future use. These colorectal cancer drugs may be even more effective than the current colorectal cancer treatment. The only way to determine if a newer therapy is better than a currently available therapy is by clinical trial participation.
Treatment decisions should be made with reference to the TNM classification system, rather than the older Dukes or the Modified Astler-Coller classification schema.
The American Joint Committee on Cancer (AJCC) and a National Cancer Institute-sponsored panel recommended that at least 12 lymph nodes be examined in patients with colon and rectal cancer to confirm the absence of nodal involvement by the tumor.[2,3,4] This recommendation takes into consideration that the number of lymph nodes examined...
This web site, developed by the nonprofit Coalition of Cancer Cooperative Groups, is an unbiased cancer clinical trial matching and navigation service enabling patients to search for cancer trials based on disease and location.